ENLIVEN THERAPEUTICS, INC. Earnings Per Share, Basic and Diluted
ENLIVEN THERAPEUTICS, INC. (ELVN) reported Earnings Per Share, Basic and Diluted of -$0.56 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-06.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-06
- ENLIVEN THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.56.
- ENLIVEN THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2021-12-31 was $0.47.
- ENLIVEN THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.55.
- ENLIVEN THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.74.
- ENLIVEN THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2021 was -$2.37.
- ENLIVEN THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2020 was -$3.53.
- ENLIVEN THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2019 was -$33.40.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$0.56 10-Q · filed 2022-05-06 | $0.14 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$0.39 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$0.97 derived: net income ÷ weighted average shares · filed 2023-11-09 |
| 2021-12-31 | $0.47 derived: net income ÷ weighted average shares · filed 2023-06-23 | -$0.05 derived: net income ÷ weighted average shares · filed 2023-06-23 | -$0.63 derived: net income ÷ weighted average shares · filed 2023-06-23 | -$2.37 10-K · filed 2022-03-15 |
| 2021-09-30 | -$0.55 10-Q · filed 2021-11-09 | -$1.26 derived: net income ÷ weighted average shares · filed 2022-10-25 | -$1.84 10-Q · filed 2021-11-09 | -$2.50 derived: net income ÷ weighted average shares · filed 2022-10-25 |
| 2021-06-30 | -$0.74 10-Q · filed 2021-08-06 | -$1.33 10-Q · filed 2021-08-06 | -$1.98 derived: net income ÷ weighted average shares · filed 2022-10-25 | -$2.70 derived: net income ÷ weighted average shares · filed 2022-10-25 |
| 2021-03-31 | -$0.58 10-Q · filed 2022-05-06 | -$1.24 derived: net income ÷ weighted average shares · filed 2022-10-25 | -$1.95 derived: net income ÷ weighted average shares · filed 2022-10-25 | -$2.55 derived: net income ÷ weighted average shares · filed 2022-10-25 |
| 2020-12-31 | -$0.65 derived: net income ÷ weighted average shares · filed 2022-03-15 | -$1.37 derived: net income ÷ weighted average shares · filed 2022-03-15 | -$1.96 derived: net income ÷ weighted average shares · filed 2022-03-15 | -$3.53 10-K · filed 2022-03-15 |
| 2020-09-30 | -$0.72 10-Q · filed 2021-11-09 | -$1.31 derived: net income ÷ weighted average shares · filed 2021-11-09 | -$2.97 10-Q · filed 2021-11-09 | -$3.83 derived: net income ÷ weighted average shares · filed 2021-11-09 |
| 2020-06-30 | -$0.59 10-Q · filed 2021-08-06 | -$2.44 10-Q · filed 2021-08-06 | -$3.46 derived: net income ÷ weighted average shares · filed 2021-11-09 | -$5.67 derived: net income ÷ weighted average shares · filed 2021-11-09 |
| 2020-03-31 | -$4.31 10-Q · filed 2021-05-11 | -$6.90 derived: net income ÷ weighted average shares · filed 2021-11-09 | -$12.92 derived: net income ÷ weighted average shares · filed 2021-11-09 | -$18.91 derived: net income ÷ weighted average shares · filed 2021-11-09 |
| 2019-12-31 | -$10.32 derived: net income ÷ weighted average shares · filed 2021-03-05 | -$19.75 derived: net income ÷ weighted average shares · filed 2021-03-05 | -$27.43 derived: net income ÷ weighted average shares · filed 2021-03-05 | -$33.40 10-K · filed 2021-03-05 |
| 2019-09-30 | -$9.43 10-Q · filed 2020-11-05 | -$17.11 derived: net income ÷ weighted average shares · filed 2020-11-05 | -$23.08 10-Q · filed 2020-11-05 | |
| 2019-06-30 | -$7.68 10-Q · filed 2020-08-14 | -$13.65 10-Q · filed 2020-08-14 | ||
| 2019-03-31 | -$5.97 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |